How Morgan Stanley Currently Rates Perrigo (NYSE:PRGO)
Morgan Stanley issued Equal-Weight rating on Perrigo (NYSE:PRGO). The firm have commenced coverage coverage on shares of PRGO in a very recent research note shared with investors and clients on Thursday morning.
From a total of 13 analysts covering Perrigo Company Plc (NYSE:PRGO) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 60% of the ratings are positive. The highest target price is $237 while the lowest target price is $156. The mean of all analyst targets is $192.54 with a 35.24% above today’s ($145.85) stock price. Perrigo Company Plc was the topic of 8 analyst reports since October 23, 2015 according to the firm StockzIntelligence Inc. B. Riley & Co maintained shares on November 24 with “Buy” rating. UBS upgraded PRGO stock in a recent report from November 16 to “Buy” rating.
Approximately 195,860 shares of stock traded hands. Perrigo Company plc Ordinary Shares (NYSE:PRGO) has declined 19.33% since April 30, 2015 and is downtrending. It has underperformed by 19.04% the S&P500.
According to Zacks Investment Research, “Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.” Get a free copy of the Zacks research report on Perrigo Company plc Ordinary Shares (PRGO).